Skip to content

MaxCyte MXCT Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin80.5%-0.4pp81.2%-0.5pp80%-6.0pp79.8%-8.6pp80.9%-7.4pp
Operating margin-141.8%-5.9pp-157.1%-24.6pp-155.6%-53.9pp-149.6%-47.7pp-135.9%-28.4pp
Net margin-121.2%-10.2pp-135.1%-28.9pp-132.6%-54.2pp-125.2%-47.3pp-110.9%-27.9pp
Returns
Return on equity-21.3%-1.7pp-23.6%-4.9pp-23.2%-7.2pp-21.7%-6.4pp-19.6%-4.2pp
Return on invested capital-25%-0.5pp-28.4%-2.8pp-28.2%-4.7pp-27%-4.1pp-24.5%-3.4pp
Efficiency
Asset turnover0.2×0.0×0.1×0.0×0.1×0.0×0.2×0.0×0.2×0.0×
Liquidity
Current ratio12×-0.2×8.3×-2.6×7.7×-2.1×12.4×-1.9×12.2×-1.0×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$1.57-16.5%$1.61-18.1%$1.69-16.7%$1.79-15.2%$1.88-13.5%
Valuation
Market capitalization$130.15M-46.8%$165.34M-62.3%$168.44M-58.6%$235.5M-42.3%$289.46M-33.6%
Price / sales-2.8×-6.4×4.9×-4.0×6.6×-2.4×7.7×-2.2×
Price / book0.8×-0.5×-1.2×0.9×-1.0×1.2×-0.6×1.5×-0.5×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are MaxCyte's profit margins?
MaxCyte (MXCT) runs a 80.5% gross margin and a -141.8% operating margin, with a -121.2% net margin.
Where do MaxCyte's ratios come from?
Every ratio is computed from MaxCyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.